drugset / Trial / NCT02095587
Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects
Non-randomizedParallel-groupOpen-labelBasic science
Summary
To evaluate the pharmacokinetics, safety, and tolerability of IPI-145 when administered to subjects with chronic hepatic impairment and in matched healthy subjects.
Timeline
- Start
- 2014-03
- Primary completion
- 2014-07
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Duvelisib | Small molecule | 25 mg | Oral |
Indications
No indication recorded.